Oncology

News

Merck puts big bucks behind ADC alliance with China's Kelun

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech tha

Oncology

After a slow start for expensive CAR-T therapies, drug devel...

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o

Oncology

Economist Impact: World Cancer Series – pharmaphorum in atte...

Taking a brief look back to pharmaphorum’s coverage of Day One of The Economist’s 8th Annual

News

EU approves AZ's Imfinzi plus chemo for advanced biliary tra...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the

News

NICE expands breast cancer patient population eligible for E...

AstraZeneca and Daiichi Sankyo's Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available

News

Gilead's Kite takes control of CAR-T partner Tmunity

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit.

Merck puts big bucks behind ADC alliance with China's Kelun

After a slow start for expensive CAR-T therapies, drug devel...

Economist Impact: World Cancer Series – pharmaphorum in atte...

EU approves AZ's Imfinzi plus chemo for advanced biliary tra...

NICE expands breast cancer patient population eligible for E...

Gilead's Kite takes control of CAR-T partner Tmunity

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks